Citius Pharmaceuticals Inc

CTXRNASDAQ · USD
0.53USD0.00 (-1.41%)
325

Citius Pharmaceuticals Inc (CTXR) Implied Volatility Current

CTXR's 30 day implied volatility is 472.24%, with an IV Rank of 63.49%. This is an average IV Rank versus the past year, meaning Citius Pharmaceuticals Inc options are fairly priced and currently offer no clear edge to buyers or sellers. CTXR's 30 day historical volatility sits at 90.89%, which means implied volatility is running 381.35 points above historical volatility, as of Nov 16, 2026.

Read more

Tracking CTXR implied volatility helps you spot when Citius Pharmaceuticals Inc options are historically cheap or expensive, and where the best trades are hiding. When CTXR IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor CTXR implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking CTXR IV rank helps you see whether CTXR's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

Implied Volatility

IV Rank
63.49%IV Rank
Moderate

IV is slightly elevated. Premiums are richer, leaning toward sellers.

Implied Volatility (30d)472.24%

IV Rank63.49%

Historical Volatility (30d)90.89%

IV Minus HV+381.35%

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →